Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Operating Leases (2019 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Operating Leases over the past 7 years, most recently at $1.4 million for Q1 2025.

  • Quarterly results put Operating Leases at $1.4 million for Q1 2025, down 71.78% from a year ago — trailing twelve months through Feb 2025 was $1.4 million (down 71.78% YoY), and the annual figure for FY2024 was $1.7 million, down 82.19%.
  • Operating Leases for Q1 2025 was $1.4 million at Lifecore Biomedical, Inc. \De\, down from $7.4 million in the prior quarter.
  • Over the last five years, Operating Leases for LFCR hit a ceiling of $17.9 million in Q1 2021 and a floor of $1.4 million in Q1 2025.
  • Median Operating Leases over the past 5 years was $7.8 million (2022), compared with a mean of $8.7 million.
  • Biggest five-year swings in Operating Leases: soared 32.96% in 2023 and later crashed 82.19% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Operating Leases stood at $11.3 million in 2021, then tumbled by 38.12% to $7.0 million in 2022, then surged by 32.96% to $9.3 million in 2023, then fell by 20.47% to $7.4 million in 2024, then crashed by 80.65% to $1.4 million in 2025.
  • The last three reported values for Operating Leases were $1.4 million (Q1 2025), $7.4 million (Q4 2024), and $4.8 million (Q3 2024) per Business Quant data.